The National Institute for Health and Care Excellence10h
Record number of positive recommendations for blood cancer treatments
Around 5,000 blood cancer patients could benefit from 13 treatments recommended by NICE in 2024. This is the largest number of positive recommendations in a single year for blood cancer treatments.
The National Institute for Health and Care Excellence12h
First-ever NHS treatment approved for advanced Hodgkin lymphoma
From today, adults with advanced Hodgkin lymphoma have access to a new treatment, after we recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use ...
The National Institute for Health and Care Excellence1d
HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging ...
National Institute for Health and Care Excellence7d
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
There is a simple discount patient access scheme for fenfluramine. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence7d
Information for the public
Lisocabtagene maraleucel (liso‑cel; Breyanzi) is available on the NHS. It is a possible treatment for large B-cell lymphoma (diffuse large B‑cell, high-grade B‑cell, primary mediastinal large B-cell ...
National Institute for Health and Care Excellence9d
Pembrolizumab with carboplatin and paclitaxel for untreated advanced or recurrent endometrial cancer [ID6381]
You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...
National Institute for Health and Care Excellence7d
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
Fenfluramine is recommended as an option for treating seizures associated with Lennox–Gastaut syndrome (LGS), as an add-on to other antiseizure medicines, for people 2 years and over. It is ...
National Institute for Health and Care Excellence5d
2 Information about blinatumomab
Blinatumomab (Blincyto, Amgen) is indicated for 'the treatment of adult patients with Philadelphia chromosome negative CD19-positive B-cell precursor leukaemia ALL in the consolidation phase'. The ...
National Institute for Health and Care Excellence7d
2 Information about lisocabtagene maraleucel
Lisocabtagene maraleucel (liso‑cel; Breyanzi, Bristol-Myers Squibb) is indicated for 'the treatment of adult patients with diffuse large B‑cell lymphoma (DLBCL), high grade B‑cell lymphoma (HGBCL), ...
National Institute for Health and Care Excellence7d
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
Fenfluramine (Fintepla, UCB) is indicated for 'the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other antiepileptic medicines for patients 2 years of age ...
National Institute for Health and Care Excellence7d
5 Evaluation committee members and NICE project team
This topic was evaluated as a single technology evaluation by the highly specialised technologies evaluation committee. The highly specialised technologies evaluation committee and the 4 technology ...